• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Katena, IOP Ophthalmics combine


Katena has announced its acquisition of IOP Ophthalmics of Costa Mesa, CA.


Denville, NJ-Katena has announced its acquisition of IOP Ophthalmics of Costa Mesa, CA.

Terms of the transaction have not been disclosed.

IOP Ophthalmics-a company that develops, commercializes, and distributes specialty ophthalmic surgical devices and biologics-holds market leadership positions with amniotic membrane technologies for ocular surface, glaucoma, and oculoplastic indications; devices for glaucoma and oculoplastic indications; and bioimplants for general ophthalmic surgeries.

“This combination of two great companies not only creates greater critical mass in the ophthalmology marketplace, but it enhances our ability to provide more clinical solutions and be of greater value to our customers,” said Bill Friedberg, president and chief executive officer of Katena.

Jason Malecka, president and founder of IOP-along with Erich Ziegler, vice president and chief financial officer of IOP-will continue their relationship with the combined company, and will continue in their roles focusing on global product growth.


For more articles in this issue of Ophthalmology Times eReport, click here.



To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.